Other languages Viracta Therapeutics, Inc.

Equities

VIRX

US92765F1084

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
0.8201 ^USD	+0.06%		-1.94%	+43.88%

04-15	Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	CI
04-01	Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	04-15
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	04-01
Viracta Therapeutics, Inc. Announces Executive Changes	03-20
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-07
Viracta Therapeutics, Inc. Provides Clinical Update	01-04
Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels	12-04
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy	31/10/23
Viracta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer	08/08/23
Viracta Therapeutics to Expand Cohort of Patients in Virus-Associated Cancers Clinical Trial	28/06/23
Viracta Therapeuticsâ€™ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma	28/06/23
Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/05/23
Viracta Therapeutics, Inc. Announces Departure of Lisa Rojkjaer as Chief Medical Officer	02/05/23
Viracta Therapeutics, Inc. Announces Nicole Onetto Will Not Stand for Re-Election as Director	31/03/23
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	13/03/23
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	13/03/23
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	13/03/23
Viracta's Lymphoma Drug Candidate Granted European Commission's Orphan Drug Designation	19/01/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Viracta Therapeutics, Inc.

Equities

VIRX

US92765F1084

Other languages

Filters